This invention discloses a drug-resistant Ewing sarcomacell line, named human Ewing sarcomacell ES 003, which was deposited at the China Center for Type Culture Collection on March 10, 2026, with accession number CCTCC NO: C202642. The cell line exhibits doxorubicin resistance; specifically, doxorubicin has an IC50 of [missing information - likely referring to an IC50 value] against the human Ewing sarcoma cell ES 003. 50 Above 5μM.
The application discloses a novel polyhydroxyalkanoate (PHA) polymerase (PhaC) which can efficiently polymerize the activated monomer 6-hydroxyhexanoate-CoA (6HHx-CoA) of 6-hydroxyhexanoate (6HHx). The PhaC is co-expressed with a CoA ligase AlkK, and can synthesize poly-epsilon-caprolactone (PCL) from the direct precursor sodium 6-hydroxyhexanoate in a halomonas sp. Halomonas which has deleted endogenous beta-ketothiolase (PhaA), acetoacetyl-CoA reductase (PhaB), PhaC and enoyl-CoA hydratase (FadB).